Obsidian Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$164.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Obsidian Therapeutics's estimated annual revenue is currently $14.7M per year.(i)
  • Obsidian Therapeutics's estimated revenue per employee is $155,000
  • Obsidian Therapeutics's total funding is $164.5M.

Employee Data

  • Obsidian Therapeutics has 95 Employees.(i)
  • Obsidian Therapeutics grew their employee count by 23% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$1.8M28367%N/AN/A
#9
$109.4M70614%N/AN/A
#10
$6.2M40233%N/AN/A

Obsidian Therapeutics, founded in 2015, aspires to extend adoptive immunotherapy to every patient with cancer. We do this by building cell therapies with pharmacologic operating systems to provide treating physicians with precise and dynamic control of engineered cells in patients. We create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs. With this unique approach, we can dramatically improve on the current generation of cell therapies. Headquartered in Cambridge, MA, Obsidian has assembled an industry-leading team of experts in immunology, cell therapy, and oncology. We continue to build our team so please check our website (www.obsidiantx.com) often for job opportunities.

keywords:Healthcare,Human Resources Hr,Pharmaceuticals

$164.5M

Total Funding

95

Number of Employees

$14.7M

Revenue (est)

23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Obsidian Therapeutics News

2022-04-13 - Obsidian Therapeutics to Present Preclinical Data from cytoTIL15 ...

Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting...

2021-09-09 - Obsidian Therapeutics : Announces Closing of $115 Million Series B Financing

CAMBRIDGE, Mass., Sept. 9, 2021 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a $115 million Series B financing with a premier syndicate of life science investors led by The Column Group Crossover ...

2021-09-09 - Obsidian Therapeutics, Inc. announced that it has received $115 million in funding from a group of investors

Obsidian Therapeutics, Inc. announced that it has raised $115 million in a round of funding led by new investor TTCG Crossover Management, LLC on September 9, 2021. The transaction included participation form Vertex Pharmaceuticals Incorporated, new investors RA Capital Management, L.P, Citadel ...

2021-09-09 - Obsidian Therapeutics Closes $115M Series B Financing

Obsidian Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies, closed a $115m Series B financing. The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel co ...

2019-09-08 - Obsidian Therapeutics Announces Strengthening of Executive ...

CAMBRIDGE, Mass., July 25, 2019 /PRNewswire/ -- Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$27.6M9542%N/A
#2
$19.4M95-10%N/A
#3
$17.3M9612%N/A
#4
$13.4M9660%N/A
#5
$13.4M96-21%N/A

Obsidian Therapeutics Executives


NameTitle
Ryan DawsChief Financial Officer
Gary VanasseSVP, Chief Medical Officer
Jan MeulenChief Scientific Officer
Paul WottonCEO, Board Member
Lee GiguereChief Legal Officer
Jennifer PetersonChief People Officer
David McGrathChief Scientific Officer
Shyam SubramanianChief Technical Officer
Jennifer OhdeChief Medical Officer
Gary VanasseSVP, Chief Medical Officer
Karen BrownSenior Vice President, Intellectual Property and Legal Affairs
Melanie CallVice President, Head of Program Management
Prakash PrabhakarVice President, Clinical Operations & Translational Early Clinical Development
Nic BettsVice President of IT and Facilities
Nicole HsuVice President Regulatory Affairs
David AubuchonVice President Finance
Kirsten KesterSenior Vice President, Business Development
Parnian Zia-AmirhosseiniVP, Regulatory Affairs & QA